SCHEDULE: Aberdeen Group Discloses 4.77% Stake in uniQure N.V.

Aberdeen Group plc and abrdn Inc. have disclosed a shared beneficial ownership of 4.77% in uniQure N.V., totaling 2,939,743 ordinary shares.

Summary

• Aberdeen Group plc and its subsidiary, abrdn Inc., reported shared beneficial ownership of 2,939,743 ordinary shares of uniQure N.V.
• This ownership represents 4.77% of uniQure N.V.'s outstanding ordinary shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Both Aberdeen Group plc and abrdn Inc. exercise shared voting and dispositive power over these 2,939,743 shares.
• The event requiring this filing occurred on September 30, 2025, with the statement filed on October 7, 2025.

Sentiment

Score: 6

Explanation: The filing is largely neutral as it is a mandatory disclosure of ownership. However, the presence of a significant institutional investor like Aberdeen Group plc holding a stake can be interpreted as a slightly positive signal for the company's stability and investment appeal.

Positives

• The disclosure confirms a significant institutional investment by Aberdeen Group plc and abrdn Inc., which can be viewed as a positive signal of confidence in uniQure N.V. by a major financial institution.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding uniQure N.V.'s future performance or operations.

Industry Context

This filing indicates continued institutional interest in the biotechnology sector, with major asset managers like Aberdeen Group plc taking positions in companies such as uniQure N.V., which specializes in gene therapy. Such disclosures are common for institutional investors managing client portfolios.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence market perception and investor confidence in uniQure N.V.

Key Dates

Recommendation

The disclosure of a significant institutional ownership stake by Aberdeen Group plc in uniQure N.V. is generally a positive indicator, suggesting confidence from a major financial institution. However, this Schedule 13G filing does not provide new operational, financial, or strategic information that would warrant a 'buy' or 'sell' recommendation. Existing investors may view this as a reaffirmation of their investment, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

uniQure N.V., Aberdeen Group plc, abrdn Inc., Schedule 13G, beneficial ownership, institutional investment, ordinary shares, N90064101